Enhancement of Chemotherapy by Pretreating Cells with Zoledronic Acid (Zometa)*
Chemotherapy using docetaxel remains an important therapy, despite the newly approved drugs, to treat hormone refractory prostate cancer. Chemotherapy improves survival, however, all men taking it will eventually become refractory to the treatment. Zoledronic acid [...]
Efficacy of Long-Term Treatment of > 5-10 Years with the LHRH Drug Leuprorelin (Lupron)
Popular culture tells us that primary androgen deprivation therapy with leuprorelin acetate (Lupron) will not work for longer than two years! This is a significant and very problematic statement given that all of us with [...]
Looking Forward Towards the Future – Zytiga or Xtandi First After Provenge
What will happen when enzalutamide (Xtandi) is approved for use in advanced prostate cancer in the disease stage prior to chemotherapy (that is if it is approved)? Already occupying this space and already approved by [...]
Limiting Lower Urinary Tract Symptoms in Men with Prostate Cancer
Prostate cancer is commonly associated with lower urinary tract symptoms (LUTS). The use of GnRH agonists or antagonists (first line ADT) is widely used as the primary treatment for advanced prostate cancer (pc) and/or to [...]
Results of the Earl Access Trial of Enzalutamide Leading to the FDA Approval
Malecare was actively involved, along with its partners, in setting up the early access trial for enzalutamide (Xtandi). The trial was conducted after the final Phase 3 AFFIRM trial that was eventually used to obtain [...]
Drunk by Chemotherapy!
Want your insurance company to pay for next drunk? According to the FDA they in fact might be willing! All kidding aside, the FDA has issued a drug safety communication regarding the risk of intoxication [...]